Kymera Therapeutics, Inc. (KYMR)
- Previous Close
28.57 - Open
29.01 - Bid 29.39 x 100
- Ask 29.84 x 100
- Day's Range
28.39 - 30.96 - 52 Week Range
19.44 - 53.27 - Volume
264,221 - Avg. Volume
748,420 - Market Cap (intraday)
1.929B - Beta (5Y Monthly) 2.19
- PE Ratio (TTM)
-- - EPS (TTM)
-2.98 - Earnings Date May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
57.67
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
www.kymeratx.comRecent News: KYMR
View MorePerformance Overview: KYMR
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KYMR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KYMR
View MoreValuation Measures
Market Cap
1.86B
Enterprise Value
1.46B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
45.55
Price/Book (mrq)
2.23
Enterprise Value/Revenue
31.00
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.65%
Return on Equity (ttm)
-36.38%
Revenue (ttm)
47.07M
Net Income Avi to Common (ttm)
-223.86M
Diluted EPS (ttm)
-2.98
Balance Sheet and Cash Flow
Total Cash (mrq)
488.74M
Total Debt/Equity (mrq)
10.50%
Levered Free Cash Flow (ttm)
-126.83M